Global Variations in Patient Radiation Exposure for Coronary Artery Disease Diagnosis: A Synthesized Review of the INCAPS 4 Findings
Posted inClinical Updates news

Global Variations in Patient Radiation Exposure for Coronary Artery Disease Diagnosis: A Synthesized Review of the INCAPS 4 Findings

This review analyzes global radiation doses in CAD diagnostic imaging based on the INCAPS 4 study. It highlights significant disparities across modalities and regions, revealing that patients in low-income countries and those undergoing CCTA face substantially higher radiation risks, necessitating urgent standardized protocols.
Beyond Objective Responses: Amivantamab Demonstrates Significant Clinical Benefit in Recurrent Adenoid Cystic Carcinoma
Posted innews Oncology Otorhinolaryngology

Beyond Objective Responses: Amivantamab Demonstrates Significant Clinical Benefit in Recurrent Adenoid Cystic Carcinoma

A Phase 2 clinical trial of amivantamab, an EGFR-MET bispecific antibody, in recurrent or metastatic adenoid cystic carcinoma (ACC) showed a 72.2% clinical benefit rate. While the primary objective response rate was low, the high rate of disease stabilization highlights its potential in managing this rare malignancy.
Posted inClinical Updates Infectious Diseases news Public Health

Long-term Immunological and Clinical Outcomes of Monkeypox Virus Infection versus MVA-BN Vaccination: A 24-Month Longitudinal Cohort Analysis

This 24-month Belgian cohort study demonstrates that natural MPXV infection induces more durable and robust immunity than MVA-BN vaccination. While clinical symptoms mostly resolve within a year, persistent scarring remains common, and vaccine-induced immunity wanes significantly, highlighting the potential need for booster strategies.
Savolitinib Plus Osimertinib Redefines Second-Line Therapy for MET-Amplified, EGFR-Mutant NSCLC: Insights from the Phase 3 SACHI Trial
Posted innews Oncology

Savolitinib Plus Osimertinib Redefines Second-Line Therapy for MET-Amplified, EGFR-Mutant NSCLC: Insights from the Phase 3 SACHI Trial

The Phase 3 SACHI trial demonstrates that the combination of savolitinib and osimertinib significantly extends progression-free survival compared to chemotherapy in patients with MET-amplified, EGFR-mutated non-small-cell lung cancer who progressed on prior TKI therapy, offering a potent oral treatment alternative.
Ensitrelvir Demonstrates Potent Antiviral Efficacy Comparable to Nirmatrelvir in Early COVID-19: Insights from the PLATCOV Trial
Posted inInfectious Diseases Internal Medicine news

Ensitrelvir Demonstrates Potent Antiviral Efficacy Comparable to Nirmatrelvir in Early COVID-19: Insights from the PLATCOV Trial

The PLATCOV trial identifies ensitrelvir as a highly effective oral antiviral, achieving rapid SARS-CoV-2 clearance comparable to ritonavir-boosted nirmatrelvir. This phase 2 adaptive trial suggests ensitrelvir is a viable alternative for outpatient management, potentially overcoming limitations associated with ritonavir-boosted regimens.